Drug Trial Radar · NCT06718101
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis
Last checked: Nov 20, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
83
Actual
Start
Dec 19, 2024
Primary completion
May 2027
Study completion May 2027
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Dec 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. The purpose of this study is to evaluate the clinical efficacy and safety of single therapies and/or combination therapies for moderate to severe AD through multiple substudies. This study will consist of multiple substudies. Substudy 1 will have a randomized, open-label period 1 followed by a lutikizumab treatment period 2 enrolling 80 participants at a 1 to 1 ratio. In Substudy 1, participants will receive subcutaneous (SC) injections of lutikizumab or matching placebo every other week for 16 weeks followed by an additional 32 weeks of SC injections of lutikizumab every other week for a total of 52 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and biomarker collections.
Conditions
- Atopic Dermatitis
Interventions
LutikizumabDrug
Subcutaneous (SC) Injection
PlaceboDrug
Subcutaneous (SC) Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16Time frame: At Week 16
- Percentage of Participants Who Reported Adverse EventsTime frame: Up to Week 52
Locations
30 sites in 4 countries. Site status is shown where the registry gives one.
Peak Dermatology Aesthetics and Wellness Fountain Hills /ID# 272550
Fountain Hills, Arizona
Dermatology Research Associates - Los Angeles /ID# 272945
Los Angeles, California
Integrative Skin Science and Research /ID# 274243
Sacramento, California
Clinical Trials Research Institute /ID# 274234
Thousand Oaks, California
Western States Clinical Res /ID# 271748
Wheat Ridge, Colorado
Skin Care Research Boca Raton /ID# 272544
Boca Raton, Florida
Research Associates of South Florida /ID# 272549
Miami, Florida
Advanced Clinical Research Institute - Tampa /ID# 272558
Tampa, Florida
Encore Medical Research - Weston /ID# 272539
Weston, Florida
Arlington Dermatology /ID# 271735
Rolling Meadows, Illinois
Somnos Clinical Research /ID# 272943
Lincoln, Nebraska
Equity Medical /ID# 272555
New York, New York
Oregon Dermatology and Research Center /ID# 271733
Portland, Oregon
Clinical Partners /ID# 271791
Johnston, Rhode Island
Health Concepts /ID# 271744
Rapid City, South Dakota
Orion Clinical Research /ID# 274236
Austin, Texas
Complete Dermatology - Sugar Land /ID# 274240
Sugar Land, Texas
Dermatology Associates of Tyler /ID# 273684
Tyler, Texas
Center for Clinical Studies - Clear Lake /ID# 271749
Webster, Texas
Medical Corporation Kojinkai Sapporo Dermatology Clinic /ID# 273619
Sapporo, Hokkaido, Japan
Kyoto University Hospital /ID# 275237
Kyoto, Kyoto, Japan
Tachikawa Dermatology Clinic /ID# 273620
Tachikawa-shi, Tokyo, Japan
Korea University Ansan Hospital /ID# 271786
Ansan-si, Gyeonggido, South Korea
Soon Chun Hyang University Hospital Bucheon /ID# 271788
Bucheon-si, Gyeonggido, South Korea
Seoul National University Hospital /ID# 271787
Seoul, Seoul Teugbyeolsi, South Korea
Konkuk University Medical Center /ID# 271789
Seoul, Seoul Teugbyeolsi, South Korea
Hallym University Kangnam Sacred Heart Hospital /ID# 271785
Seoul, Seoul Teugbyeolsi, South Korea
Royal Liverpool University Hospital /ID# 272584
Liverpool, United Kingdom
Royal United Hospital /ID# 274328
Bath, Bath And North East Somerset, United Kingdom
Chapel Allerton Hospital /ID# 274762
Leeds, West Yorkshire, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.